1. The Correspondent by Virginia Evans (Crown: $28) A lifelong letter writer reckons with a painful past. 2. Half His Age by Jennette McCurdy (Ballantine Books: $30) A teenager embarks on a secret ...

Discontinuing the use of GLP-1 weight-loss medications triggers weight regain more than previously thought, a new study suggested. The research, which was published in The BMJ, found that stopping the ...

AI and automation are reshaping jobs, but human skills remain essential. Top future career courses: AI, data science, cybersecurity, sustainability. Tech MBAs and engineering management link business ...

It has been two years since Phoenix Suns shooting guard Devin Booker's first signature Nike basketball shoe launched in extremely limited numbers at Art Basel. After dropping in every style imaginable ...

Off the rip, a big standout to me in this sale is just how many new releases are eligible for the promo. And when I say new, I mean new. Two of our top picks to look forward to in September are ...

People who consumed the highest levels of certain artificial sweeteners — equivalent to just one diet soda a day — saw a significant decline in their ability to remember and recall words when compared ...

Share on Pinterest A new study observed that people taking GLP-1 drugs had improved asthma symptoms. Felix Hörhager/picture alliance via Getty Images Researchers based in the United Kingdom recently ...

In recent years, numerous plaintiffs—including publishers of books, newspapers, computer code, and photographs—have sued AI companies for training models using copyrighted material. A key question in ...

Veronica Paulus is a former STAT intern supported by the Harvard University Institute of Politics. GLP-1 drugs could treat more than just diabetes and obesity. They may also reduce migraine frequency.

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. People with diabetes who were taking GLP-1 ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants. The historically tight-lipped Amgen execs remain judicious with ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...